CIPROFLOXACIN IN DEXTROSE 5% Drug Patent Profile

« Back to Dashboard

Which patents cover Ciprofloxacin In Dextrose 5%, and what generic alternatives are available?

Ciprofloxacin In Dextrose 5% is a drug marketed by Hikma Farmaceutica, Baxter Hlthcare, Baxter Hlthcare Corp, Bedford, Hospira, Inforlife, and Teva Pharms. and is included in eight NDAs.

The generic ingredient in CIPROFLOXACIN IN DEXTROSE 5% is ciprofloxacin. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ciprofloxacin In Dextrose 5%

A generic version of CIPROFLOXACIN IN DEXTROSE 5% was approved as ciprofloxacin by HIKMA FARMACEUTICA on December 22^nd, 2009.

Summary for CIPROFLOXACIN IN DEXTROSE 5%

US Patents:	0
Applicants:	7
NDAs:	8
Finished Product Suppliers / Packagers:	3
Clinical Trials:	327
DailyMed Link:	CIPROFLOXACIN IN DEXTROSE 5% at DailyMed

Recent Clinical Trials for CIPROFLOXACIN IN DEXTROSE 5%

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Faiz ur rahman	NA
Stanford University	EARLY_PHASE1
Uppsala Clinical Research Center, Sweden	PHASE4

See all CIPROFLOXACIN IN DEXTROSE 5% clinical trials

US Patents and Regulatory Information for CIPROFLOXACIN IN DEXTROSE 5%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma Farmaceutica	CIPROFLOXACIN IN DEXTROSE 5%	ciprofloxacin	INJECTABLE;INJECTION	076757-001	Apr 21, 2008		DISCN	No	No
Bedford	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	078114-002	Mar 18, 2008		DISCN	No	No
Baxter Hlthcare Corp	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	078024-001	Mar 18, 2008		DISCN	No	No

Ciprofloxacin in Dextrose 5% Market Dynamics, Patent Status, and Financial Trajectory

Last updated: October 3, 2026

Ciprofloxacin in Dextrose 5% is a mature, generic intravenous antibiotic market with limited patent protection, low product differentiation, and price competition among hospital suppliers. The product’s commercial value depends mainly on hospital purchasing contracts, supply reliability, manufacturing economics, and antimicrobial demand rather than exclusivity. Product-level revenue is not publicly disclosed by most suppliers, but the financial trajectory is consistent with a late-life injectable generic: declining nominal prices, periodic shortages, and stable baseline demand.

What is ciprofloxacin in Dextrose 5%?

Ciprofloxacin in Dextrose 5% is an intravenous formulation of ciprofloxacin lactate diluted in 5% dextrose solution. It is supplied primarily in premixed containers for hospital administration.

Product characteristic	Typical specification
Active ingredient	Ciprofloxacin lactate
Delivery route	Intravenous infusion
Diluent	5% dextrose injection
Common presentations	200 mg/100 mL and 400 mg/200 mL
Typical concentration	2 mg/mL
Primary buyers	Hospitals, integrated delivery networks, group purchasing organizations
Regulatory category	Prescription generic injectable
Primary competitors	Other ciprofloxacin IV products, levofloxacin, moxifloxacin, ceftriaxone and other hospital antibiotics

The FDA-approved labeling includes treatment of susceptible bacterial infections involving the urinary tract, respiratory tract, skin, bones and joints, abdominal cavity, and other sites. Ciprofloxacin is also used for specific anthrax and plague-related indications, subject to regulatory labeling and clinical guidance. Its use is constrained by fluoroquinolone safety warnings and antimicrobial stewardship policies. (U.S. Food and Drug Administration [FDA], 2018)

When did ciprofloxacin lose exclusivity?

Ciprofloxacin lost meaningful U.S. market exclusivity years ago. The original Cipro product was commercialized by Bayer, and the core ciprofloxacin patent estate expired in the early 2000s. Generic competition subsequently expanded across oral and injectable presentations.

The commercial result was a shift from branded pharmaceutical economics to hospital-generic economics:

• No remaining composition-of-matter exclusivity protects the active ingredient.
• The original branded product no longer controls the injectable market.
• Generic manufacturers compete primarily on price, contract access and supply continuity.
• Any remaining formulation or manufacturing patents are not commercially material barriers to standard ciprofloxacin in Dextrose 5% presentations.

The product is therefore not an attractive target for a new entrant seeking patent-based price protection. Its value is based on manufacturing scale and procurement access.

What is the Orange Book status of ciprofloxacin in Dextrose 5%?

The Orange Book contains reference-listed-drug information and approved generic equivalents for ciprofloxacin products, but the regulatory status varies by dosage form, strength, sponsor and marketing status. The FDA identifies whether a listed product is active, discontinued or not currently marketed. (FDA, 2024a)

For ciprofloxacin in Dextrose 5%, the practical Orange Book position is:

Issue	Market implication
Reference product	Historical branded ciprofloxacin injection product
Generic equivalents	Multiple ANDA-based injectable products have been approved over time
Patent blocking risk	Low for standard premixed IV presentations
Therapeutic equivalence	Determined by FDA product-specific requirements
Current commercial status	Predominantly generic and hospital-contract driven
Orange Book value	Useful for approval and equivalence analysis, not for identifying a meaningful remaining exclusivity period

Not every approved generic is continuously marketed. Injectable manufacturers may retain approvals while discontinuing commercial supply because of low margins, manufacturing changes, facility constraints or portfolio rationalization.

How many patents protect ciprofloxacin in Dextrose 5%?

No material patent estate currently protects the active ingredient or the standard clinical use of ciprofloxacin in Dextrose 5%. The original ciprofloxacin patents expired long ago.

What formulation patents remain relevant?

The standard product uses established ingredients and a conventional intravenous presentation. Relevant intellectual-property issues may include:

• Container and closure systems.
• Manufacturing processes.
• Stability methods.
• Premix packaging.
• Device or infusion-system compatibility.
• Proprietary manufacturing know-how.

These rights generally do not create broad market exclusivity for ciprofloxacin in Dextrose 5%. A competitor can usually enter through an ANDA if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence or applicable injectable-product standards, sterility, stability and labeling.

Are method-of-use patents a barrier?

Method-of-use patents are not a meaningful barrier for the established indications associated with ciprofloxacin injection. Fluoroquinolone use is governed more by label restrictions, resistance patterns, safety warnings and hospital protocols than by patent rights.

When does ciprofloxacin in Dextrose 5% lose exclusivity?

The product has already lost exclusivity. There is no commercially relevant future loss-of-exclusivity event comparable to a branded drug facing its first generic entrant.

The market timeline is better described as follows:

Period	Market development
1980s-1990s	Bayer-led branded ciprofloxacin commercialization
Early 2000s	Expiration of core ciprofloxacin patent protection
2000s	Expansion of generic oral and injectable competition
2010s	Hospital consolidation, contract purchasing and low-price competition
2020s	Mature sterile-injectable market with periodic supply disruption and limited pricing power

The main forecast variable is not patent expiry. It is the number of active suppliers and the reliability of their sterile manufacturing operations.

Which companies compete in the ciprofloxacin IV market?

Competition varies by country and presentation. U.S. hospital suppliers have included large generic and injectable manufacturers such as Baxter, Fresenius Kabi, Sandoz, Hikma and other ANDA holders. Product availability can change when a company discontinues a presentation or transfers manufacturing.

How does ciprofloxacin compare with competing hospital antibiotics?

Product	Competitive position
Ciprofloxacin IV	Established gram-negative coverage; inexpensive; safety and resistance limitations
Levofloxacin IV	Broad fluoroquinolone alternative; often competes in respiratory and urinary infections
Moxifloxacin IV	Stronger respiratory positioning but weaker gram-negative and urinary utility
Ceftriaxone IV	Major hospital substitute in several infection categories; often lower operational complexity
Piperacillin/tazobactam	Broader empiric hospital coverage; different clinical and pricing profile
Meropenem	Reserved for serious resistant infections; higher clinical and economic value
Aztreonam	Alternative for selected beta-lactam allergy cases

Ciprofloxacin does not compete solely against other ciprofloxacin suppliers. Hospital formularies compare the drug against therapeutic alternatives, local resistance data, stewardship policies, and total treatment cost.

What is the FDA regulatory status?

Ciprofloxacin injection is an FDA-approved prescription product. The regulatory burden for new suppliers remains significant because sterile injectable products require validated aseptic processing, facility controls, container-closure integrity, stability data and compliance with current good manufacturing practice requirements.

The most important regulatory constraints are:

1. Fluoroquinolone class warnings, including risks involving tendons, peripheral nerves, the central nervous system and other serious adverse reactions.
2. Antimicrobial stewardship restrictions.
3. Local resistance and susceptibility requirements.
4. Sterile-manufacturing compliance.
5. Labeling and presentation-specific requirements for premixed products.

The FDA has also issued broad safety communications concerning systemic fluoroquinolones. These communications can reduce use in uncomplicated infections and shift prescribing toward alternative antibiotics. (FDA, 2018)

Is there biosimilar risk for ciprofloxacin in Dextrose 5%?

There is no biosimilar risk. Ciprofloxacin is a small-molecule chemical drug, not a biologic. Competition occurs through the ANDA pathway and generic-drug substitution rules, not through the U.S. biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive risks are:

• Additional ANDA approvals.
• Re-entry by previously inactive suppliers.
• Contract losses to lower-cost manufacturers.
• Therapeutic substitution with other antibiotics.
• Hospital formulary restrictions.
• Supply disruptions that cause temporary share gains or losses.

What is the financial trajectory of ciprofloxacin in Dextrose 5%?

The product has a mature, low-growth financial profile. Public companies generally report ciprofloxacin injection within broader generic or hospital-product categories, so product-level revenue and margin data are rarely available.

Revenue trajectory

The likely revenue path is:

1. Branded period: High prices and substantial value tied to Bayer’s proprietary franchise.
2. Generic entry: Rapid price erosion and volume redistribution.
3. Mature generic period: Stable unit demand but low average selling prices.
4. Supply-constrained periods: Temporary revenue and price increases for manufacturers with available inventory.
5. Long-term period: Flat or declining nominal revenue unless shortages, tenders or geographic expansion improve pricing.

Demand is relatively resilient because hospitals maintain baseline use of injectable antibiotics. Revenue growth is limited because treatment volumes are constrained by generic substitution, antimicrobial stewardship and substitution by competing agents.

Margin drivers

Driver	Effect on economics
API cost	Direct impact on gross margin
Sterile manufacturing utilization	Low utilization increases unit cost
Container and packaging costs	Important for premixed presentations
Hospital contract pricing	Often compresses ASP
GPO participation	Expands access but reduces pricing power
Manufacturing quality events	Can eliminate supply and increase remediation cost
Shortages	May improve short-term pricing for available suppliers
Freight and cold-chain requirements	Affect delivered cost, although the product is not generally a biologic

The strongest economic advantage belongs to suppliers with large sterile facilities, efficient fill-finish operations and reliable hospital distribution. Smaller manufacturers may obtain volume during shortages but face greater exposure to fixed costs, quality remediation and customer concentration.

What generic entry risks exist?

Generic entry risk is already fully realized. The remaining risk is share migration among active suppliers rather than an initial loss of exclusivity.

A supplier holding a commercial position can lose revenue through:

• A new low-cost ANDA competitor.
• A hospital tender rebid.
• GPO contract changes.
• Product discontinuation by a major customer.
• Failure to maintain FDA manufacturing compliance.
• A competitor resolving a shortage faster.
• Therapeutic conversion to ceftriaxone, levofloxacin or another alternative.

For investors and licensors, supply continuity is more important than patent duration. A supplier with a strong manufacturing record and multiple approved presentations may have more commercial value than a supplier with a nominally broader patent position.

What patent litigation or Paragraph IV challenges affect the product?

No major current Paragraph IV litigation is central to the commercial outlook for standard ciprofloxacin in Dextrose 5%. Paragraph IV challenges were relevant during the original generic-entry period, but the product is now a mature generic.

Current legal exposure is more likely to involve:

• FDA inspection findings.
• Product liability claims.
• Antitrust or contracting disputes.
• Manufacturing and supply agreements.
• Intellectual-property disputes concerning packaging or production technology.

There is no meaningful settlement-driven exclusivity structure comparable to those seen in recently launched branded drugs.

Are licensing deals important for ciprofloxacin in Dextrose 5%?

Licensing is not a major value driver for the mature U.S. product. Commercial arrangements generally involve:

• Contract manufacturing.
• Authorized distribution.
• Hospital supply agreements.
• Regional commercialization rights.
• API procurement.
• Portfolio transfers between generic manufacturers.

These arrangements can affect product availability and revenue allocation, but they do not usually create durable exclusivity. The most valuable agreements are likely to be supply contracts with hospital systems, wholesalers or GPOs rather than patent licenses.

What geographic markets offer the strongest opportunity?

The United States remains a large hospital market but has intense price competition and demanding sterile-manufacturing standards. Other markets may offer better unit margins but greater regulatory, tender and reimbursement risk.

Geography	Commercial profile
United States	Large demand, low pricing, concentrated buyers, high compliance burden
Europe	National and regional tenders, strong generic substitution
Emerging markets	Wider price dispersion, variable regulation, local manufacturing advantages
Hospital-focused export markets	Opportunity depends on registration, tenders and supply reliability

Geographic expansion can increase volume, but the product is unlikely to support premium pricing without a differentiated delivery system, shortage position or local supply advantage.

How strong is the patent estate for ciprofloxacin in Dextrose 5%?

The patent estate is weak from a market-exclusivity perspective. The product has:

• No relevant active composition patent.
• No meaningful exclusivity for standard indications.
• Limited potential protection from conventional formulation features.
• Low litigation value compared with recently launched branded drugs.
• Greater dependence on regulatory compliance and manufacturing execution.

The strongest barriers are operational rather than legal. Sterile production, FDA compliance, product registration and hospital contracting can slow entry, but they do not prevent competition permanently.

Key Takeaways

• Ciprofloxacin in Dextrose 5% is a mature generic injectable antibiotic.
• Core patent and exclusivity protection expired years ago.
• The product is marketed through ANDA-based competition rather than branded exclusivity.
• Orange Book analysis is relevant to approval status but does not identify a meaningful remaining patent barrier.
• There is no biosimilar pathway because ciprofloxacin is a small-molecule drug.
• Product-level revenue is generally not disclosed by manufacturers.
• The financial trajectory is characterized by low prices, stable baseline hospital demand and occasional shortage-driven pricing.
• Manufacturing reliability, sterile capacity and hospital contracts are more important than patents.
• Major commercial risks include additional generic competition, supplier discontinuations, GPO pricing and therapeutic substitution.
• The product has limited licensing and litigation value absent a differentiated delivery platform or supply-constrained market position.

FAQs

What is the typical strength of ciprofloxacin in Dextrose 5%?

Common premixed presentations are 200 mg in 100 mL and 400 mg in 200 mL of 5% dextrose injection, generally at a concentration of 2 mg/mL.

Is ciprofloxacin in Dextrose 5% still profitable?

It can be profitable for manufacturers with efficient sterile capacity, large hospital contracts and reliable supply. Profitability is generally limited by generic pricing and high fixed manufacturing costs.

Can a company obtain new exclusivity for a ciprofloxacin premix?

A new product could potentially receive protection for a genuinely novel formulation, container, device or delivery system. A conventional ciprofloxacin-in-Dextrose 5% premix is unlikely to support meaningful new market exclusivity.

Does FDA approval of a new ciprofloxacin supplier create a 180-day generic exclusivity period?

A first-approved ANDA may qualify for 180-day exclusivity if statutory conditions are met, but that issue is tied to the relevant reference product and patent certification history. It is not a recurring commercial exclusivity mechanism for an established generic market.

What is the principal investment risk in this product?

The principal risk is margin compression from hospital contracting and supplier competition, followed by manufacturing disruption. Patent expiry is no longer the central risk because the market is already generic.

References

1. U.S. Food and Drug Administration. (2018). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024b). DailyMed: Ciprofloxacin in dextrose injection labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
4. U.S. Food and Drug Administration. (2024c). Abbreviated new drug application process. https://www.fda.gov
5. U.S. Food and Drug Administration. (2023). Drug shortages: Injectable antibiotics and supply information. https://www.fda.gov